(Press-News.org) A single test to speed up diagnosis of a serious disease in pregnant women does not need to be repeated, new research has found.
Results from the PARROT-2 trial, published today in the Lancet by researchers from King’s College London and funded by Jon Moulton Charitable Trust, Tommy’s Charity and the National Institute for Health and Care Research, has ruled out the need for routine repeat placental growth factor-based testing (PIGF) for all women with suspected pre-eclampsia.
PARROT-2 is a large, multi-centre UK trial in 1,252 women with suspected preterm pre-eclampsia, a life-threatening condition for pregnant women, and their babies, that can lead to major complications, such as stillbirth and neonatal death, as well as longer hospital stays.
PIGF testing is a blood test that can detect levels of placental growth factor and soluble flt-1, which are biomarkers for pre-eclampsia. An abnormal result will identify those women and babies at higher risk of adverse outcomes, who need intensive surveillance, whilst a normal result means women can be safely discharged home to continue with normal antenatal care. Use of an initial test in pregnancy was rolled out across much of England in 2021.
The findings show that repeat testing enabled faster diagnosis of pre-eclampsia, but this did not translate into better outcomes for women or their babies.
Dr Alice Hurrell, first author of the study from King’s College London, said: “This large trial has major implications for policy, practice, and guidelines. Universal, routine repeat testing, as recommended by some international groups, is not supported by our findings. However, the clinical benefit of a one-off placental growth factor-based test when pre-eclampsia is first suspected, remains clear.”
Professor Lucy Chappell, NIHR Senior Investigator from King’s College London, said: “Pregnant women repeatedly tell us the value of having greater certainty on diagnosis. These trial results should further lower the barriers to widespread equitable adoption of initial placental growth factor-based testing, improving maternal health outcomes globally. With an estimated 5% of all women affected by preterm hypertension in pregnancy (around 7 million pregnancies worldwide), this is now a pivotal time to ensure that placental growth factor-based testing can reach widespread implementation across healthcare settings.”
Marcus Green, CEO of Action on Pre-eclampsia, said: “These are really important findings showing that once the first test has been done, there is nothing to be gained from further testing. A single test can assure women with certainty if they are likely or unlikely to get pre-eclampsia. We look forward to completion of roll-out of placental growth factor-based testing across England, with an urgent call for implementation in the devolved administrations across all four nations. These new results also provide a timely opportunity to tackle the higher burden of adverse outcomes due to pre-eclampsia in global settings.”
Kath Abrahams, Chief Executive of Tommy’s, said: “This important study funded by Tommy’s is a significant and positive step forwards in the drive to reduce the harm caused by pre-eclampsia.
“Following the breakthrough made by the previous Tommy’s funded PARROT study, we hope it will pave the way for PlGF testing for all women and birthing people who are thought to be at risk of pre-eclampsia, so that those most in need can be offered vital extra monitoring and support.”
NOTES TO EDITORS:
Professor Lucy Chappell is Chief Scientific Adviser to the Department of Health and Social Care and CEO of the NIHR.
About King’s College London
King’s College London is amongst the top 40 universities in the world and top 10 in Europe (THE World University Rankings 2024), and one of England’s oldest and most prestigious universities. With an outstanding reputation for world-class teaching and cutting-edge research, King’s maintained its sixth position for ‘research power’ in the UK (2021 Research Excellence Framework).
King's has more than 33,000 students (including more than 12,800 postgraduates) from some 150 countries worldwide, and 8,500 staff.
For nearly 200 years, King’s students and staff have used their knowledge and insight to make a positive impact on people, society and the planet. Focused on delivering positive change at home in London, across the UK and around the world, King’s is building on its history of addressing the world’s most urgent challenges head on to accelerate progress, make discoveries and pioneer innovation. Visit the website to find out more about Vision 2029, which sets out bold ambitions for the future of King’s as we look towards our 200th anniversary.
World-changing ideas. Life-changing impact: kcl.ac.uk/news
We’re Tommy’s, the leading charity that exists to stop the heartbreak and devastation of baby loss and make pregnancy and birth safe – for everyone. To do this, we work across the whole pregnancy journey to drive change at every level – translating our research breakthroughs into new tests and treatments in clinical care, changing national maternity policy and providing expert information and support for anyone who needs it. Together, with the strength of our community, we’re saving babies’ lives.
Repeat testing for pre-eclampsia does not lead to better outcomes for pregnant women, but a single test is still beneficial
ELSE PRESS RELEASES FROM THIS DATE:
Industrial pollution leaves its mark in Mediterranean corals
UCL Press Release Under embargo until Friday 9 February, 00:01 UK time Industrial pollution leaves its mark in Mediterranean corals For the first time, pollutants from burning fossil fuels have been found embedded in corals, offering scientists a potential new tool to track the history of pollution, finds a new study led by UCL researchers. The study, published in the journal Science of the Total Environment, identified carbon particles emitted by burning fossil fuels embedded in the corals of Illa Grossa Bay, off the Columbretes Islands in the Mediterranean Sea. Finding this type of pollution – known as fly-ash or spheroidal carbonaceous particles (SCPs) ...
Urgent call for antitrust measures to safeguard innovation in spatial biology
Recent breakthroughs in spatial biology technology have transformed biomedical research; however, legal disputes are preventing small, innovative companies from advancing new technologies and ideas. Ongoing litigation poses a threat to the progress of even the most promising scientific technologies and the potential discoveries they could enable, according to the authors of the exclusive article titled “Sounding an Alarm Over Spatial Biology,” in Genetic Engineering and Biotechnology News (GEN). Click here to read the article ...
Pre-diabetes gets its due: New $1.2 million award aimed at early intervention and treatment
SAN ANTONIO, Feb. 8, 2024 – More than one out of three people have pre-diabetes, characterized by abnormal blood sugar levels not yet in the diabetes range – and yet associated with significant increases in eye, kidney and neuropathic diseases, and risk of cardiovascular death. Moreover, the number of people with the condition is expected to double by 2030, with prevalence substantially higher in minority populations, including Hispanics. Both pre-diabetes and diabetes are considered global epidemics. As pre-diabetes largely is underdiagnosed and undertreated, ...
Celebrating excellence in anatomy: AAA awards distinguished members
ROCKVILLE, MD – February 8, 2024 – The American Association for Anatomy (AAA) is honored to announce its 2024 awards recipients. Eighteen of the association’s 2,455 members have been selected because they advanced AAA’s values: community, respect, inclusion, integrity, and discovery. The AAA awards program provides over $650,000 in awards, research grants, and scholarships annually. Many recipients go on to achieve significant success in their careers. "We, as anatomy ...
Athira Pharma announces publication in Frontiers in Neuroscience highlighting therapeutic potential of ATH-1105 in amyotrophic lateral sclerosis (ALS)
BOTHELL, WA, Feb. 8, 2024 — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced publication of research highlighting the neuroprotective and anti-inflammatory effects of ATH-1105 in preclinical models of amyotrophic lateral sclerosis (ALS). The original research article, “ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALS,” authored by Berthiaume, A., and Reda, S., et al., was published ...
Sex hormones help gonorrhea fight off antimicrobials and antibiotics
DURHAM, N.C. – You know that package warning that oral birth control won’t prevent STIs? Well in the case of gonorrhea, the sexually transmitted bacterium that causes the disease can use those hormones to help it resist antibiotic attacks. Like many bacteria, this bug, Neisseria gonorrhoeae, is equipped with pumps to push the killing chemicals out of its cells. But what’s unique, according to a Duke and Emory study online this week in Nature Communications, is that the hormones of the human urogenital tract actually allow gonorrhea to make and use more of these pumps to fight intrinsic ...
45 finalists named for the 2024 Hertz Fellowships
The Fannie and John Hertz Foundation today announced 45 finalists for the 2024 Hertz Fellowships in applied science, mathematics and engineering. Selected from more than 860 applicants and representing 21 universities, the finalists advance to a culminating round of interviews for one of the most competitive and coveted doctoral fellowships in the nation. The 2024 class of Hertz Fellows will be announced in May. Since 1963, the Hertz Foundation has granted fellowships empowering the nation’s most promising young ...
How one type of lung cancer can transform into another
Lung tumors called adenocarcinomas sometimes respond to initially effective treatments by transforming into a much more aggressive small cell lung cancer (SCLC) that spreads rapidly and has few options for treatment. Researchers at Weill Cornell Medicine have developed a mouse model that illuminates this problematic process, known as histological transformation. The findings advance the understanding of how mutated genes can trigger cancer evolution and suggest targets for more effective treatments. The researchers, whose results were published ...
Results from South Pole Telescope’s new camera emerge
Argonne is part of a multi-institutional effort to survey the sky for clues about the origins and nature of our universe. For more than five years, scientists at the South Pole Telescope in Antarctica have been observing the sky with an upgraded camera. The extended gaze toward the cosmos is picking up remnant light from the universe’s early formation. Now researchers have analyzed an initial batch of data, publishing details in the journal Physical Review D. The results from this limited dataset hint at even more powerful future insights about the nature of our universe. The telescope at the Amundsen-Scott South Pole Station, which is operated by the National ...
Rosenthal Department of Management established at McCombs School of Business
AUSTIN, Texas — The Management Department in the McCombs School of Business at The University of Texas at Austin has long been recognized as a powerhouse for research excellence and teaching innovation. Now, it holds a new distinction. It is the first academic department in the business school to be named as the result of a generous gift. The newly named Rozanne and Billy Rosenthal Department of Management has been made possible by a $25 million gift from two married Longhorns, Rozanne Rosenthal, B.S. ’74, and Billy Rosenthal, BBA ’72. ...